Article summary
Leading psychedelic biotech company Biomind Labs Inc. (NEO: BMND) (OTC: BMNDF) (FSE: 3XI) has announced the completion of dose administration to 30 healthy subjects with Treatment-Resistant Depression in the Phase II clinical trial for novel drug candidate BMND01. Biomind Labs are focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological and psychiatric disorders by scientifically harnessing the medicinal power of psychedelic molecules. The goal of Biomind Labs is to use medical breakthroughs to create new nanotech delivery systems that can adequately address a range of psychiatric and neurological issues. Biomind Laboratories is using its acceleration The post Biomind Labs Complete Phase II Dosing of DMT-Based BMND01 for Treatment-Resistant Depression appeared first on Psychedelic Chronicle.
Continue to the original publication for the complete article.